Document is current
Any future updates will be listed below
-
Authors
Borchers, Lauren R.
Dan, Rotem https://orcid.org/0000-0003-4341-330X
Belleau, Emily L. https://orcid.org/0000-0001-9024-468X
Kaiser, Roselinde H. https://orcid.org/0000-0002-0369-0583
Clegg, Rachel
Goer, Franziska
Pechtel, Pia
Beltzer, Miranda
Wooten, Dustin
El Fakhri, Georges
Normandin, Marc D.
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH068376, MH095809)
- License Information
-
More Information
Article History
Received: 3 March 2025
Revised: 31 July 2025
Accepted: 28 August 2025
First Online: 9 September 2025
Competing interests
: Over the past 3 years, DAP has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, Neuroscience Software, and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) as well as Alkermes; he has received research funding from the BIRD Foundation, Brain and Behavior Research Foundation, Dana Foundation, Millennium Pharmaceuticals, National Institute Mental Health, and Wellcome Leap; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. MB is employed by Lyra Health and Lyra Clinical Associates, receives income from Lyra Health and Lyra Clinical Associates, and has been granted equity in Lyra Health. All other authors report no financial relationships with commercial interests.
